Emergent BioSolutions Inc
XBER:ER4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Emergent BioSolutions Inc
XBER:ER4
|
US |
|
B
|
Boeing Co
XHAN:BCO
|
US |
|
E
|
E&E Recycling Inc
TPEX:8440
|
TW |
|
S
|
Surteco Group SE
F:SUR
|
DE |
|
F
|
Fauji Fertilizer Company Ltd
KAR:FFC
|
PK |
|
F
|
Freehold Royalties Ltd
F:1FH
|
CA |
|
B
|
Basler AG
XMUN:BSL
|
DE |
|
Goldplat PLC
LSE:GDP
|
UK |
Wall St Price Targets
ER4 Price Targets Summary
Emergent BioSolutions Inc
According to Wall Street analysts, the average 1-year price target for ER4 is 16.61 EUR with a low forecast of 16.44 EUR and a high forecast of 17.09 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ER4's stock price target?
Price Target
16.61
EUR
According to Wall Street analysts, the average 1-year price target for ER4 is 16.61 EUR with a low forecast of 16.44 EUR and a high forecast of 17.09 EUR.
What is the Revenue forecast for Emergent BioSolutions Inc?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 7 years is 4%.
What is the Gross Profit forecast for Emergent BioSolutions Inc?
Projected CAGR
-9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 4%. The projected CAGR for the next 1 year is -9%.
What is the Operating Income forecast for Emergent BioSolutions Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 7 years is 17%.
What is the Net Income forecast for Emergent BioSolutions Inc?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 1 year is 4%.
